Grace Koennecke's profile photo

Grace Koennecke

Athens

Managing Editor at ACRN (Athens, OH)

@ohiou | dj, reviews editor @acrn | web editor for @vrntmagazine | 2024 White House Correspondents’ Association Scholar

Featured in: Favicon giemedia.com Favicon thepostathens.com Favicon clevelandmagazine.com Favicon aerospacemanufacturinganddesign.com Favicon todaysmedicaldevelopments.com Favicon acrn.com Favicon newsbreak.com Favicon medicaleconomics.com Favicon ophthalmologytimes.com (+1) Favicon optometrytimes.com

Articles

  • Online Survey Reveals Clinicians’ Top Concerns in BDI, Schizophrenia Treatment

    2 weeks ago | psychiatrictimes.com | Grace Koennecke

    Findings from a recent online research study by The Harris Poll indicated that clinicians are concerned about their patients’ quality of life as well as medications issues like adherence and switching.

  • Eyenovia, Betaliq enter potential reverse merger agreement

    4 weeks ago | optometrytimes.com | Grace Koennecke

    Eyenovia recently announced its entrance into a non-binding letter of intent debating a potential reverse merger transaction with Betaliq, a clinical stage pharmaceutical company with a therapeutic focus on glaucoma. The potential merger would create a new ophthalmic company that pairs two FDA-approved technologies – Betaliq’s EyeSOl water-free drug delivery technology for use in glaucoma and Eyenovia’s Optejet topical ophthalmic liquid dispensing platform.

  • ZEISS VISULAS Combi availability expands to Canada

    1 month ago | ophthalmologytimes.com | Grace Koennecke

    ZEISS Medical Technology announced the availability of its ZEISS VISULAS Combi, an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution, in Canada. The treatment is designed for retina, cataract, and glaucoma conditions, streamlining workflow with custom modules, a uniform interface, and space-saving features.

  • HanAll Biopharma receives Orphan Drug Designation in Japan for Batoclimab for thyroid eye disease

    1 month ago | ophthalmologytimes.com | Grace Koennecke

    HanAll Biopharma received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Batoclimab, an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

  • Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

    1 month ago | ophthalmologytimes.com | Grace Koennecke

    Innovent Biologics announced the approval of SYCUME, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, for the treatment of thyroid eye disease (TED). The treatment was approved by China’s National Medical Products Administration (NMPA) and is the nation’s first and the world’s second approved IGF-1R antibody drug. After 70 years, SYCUME is the newest treatment option for TED in China.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
186
Tweets
1K
DMs Open
No
grace koennecke
grace koennecke @grace_koe3
20 Apr 25

https://t.co/dctf0Pghn6

grace koennecke
grace koennecke @grace_koe3
11 Apr 25

https://t.co/4r0kpvwMFM

grace koennecke
grace koennecke @grace_koe3
9 Apr 25

Today, I was so excited to present my senior thesis through the Honors Tutorial College at Ohio University, titled "Exploring the Last 25 Years of Hip-Hop and its Implications." https://t.co/tWjoCq1Fnl